Read by QxMD icon Read

Cutaneous lymphoma

shared collection
87 papers 25 to 100 followers
By Rosa Izu Dermatologist. Associated Professor of Dermatology. Medicine. Basque Country University
Ajith P Kannangara, Denise Levitan, Alan B Fleischer
BACKGROUND: Various combination therapies are used in refractory cutaneous T-cell lymphoma (CTCL). Although bexarotene has been studied in combination with psoralen photochemotherapy (PUVA), IFN-alpha and denileukin difitox, there have been no published data assessing the efficacy of the combination of bexarotene and methotrexate. OBJECTIVE: To evaluate the efficacy and safety of an oral bexarotene and methotrexate combination for the treatment of refractory CTCL...
2009: Journal of Dermatological Treatment
Hatice Sanli, Bengu Nisa Akay, Muhit Ozcan
There are several reports of patients who developed extracutaneous lymphoma after they started bexarotene treatment. The authors report a case in which the initiation of bexarotene therapy for Sézary syndrome was temporally associated with the development of Hodgkin's lymphoma despite improvement in cutaneous signs and symptoms. It is possible that bexarotene may contribute to the development of extracutaneous lymphoma. Although bexarotene therapy may relieve symptoms and signs of cutaneous T-cell lymphoma, careful examination of the lymph nodes during treatment is recommended...
August 2010: Journal of Drugs in Dermatology: JDD
Neha Mehta, Alan S Wayne, Youn H Kim, Gregory A Hale, Carlos S Alvarado, Patricia Myskowski, Elaine S Jaffe, Klaus J Busam, Melissa Pulitzer, Jeffrey Zwerner, Steven Horwitz
INTRODUCTION: Subcutaneous panniculitis-like T-cell lymphoma (SPTL-AB) and cutaneous gamma/delta T-cell lymphoma (CGD-TCL) are rare T-cell lymphomas with varying clinical courses. There is no standard treatment, although chemotherapy and hematopoietic stem cell transplantation are commonly used. We describe results using bexarotene for children and adults with these disorders. METHODS: We identified 15 patients (12 adults, 3 children) who were treated with bexarotene between 2000 and 2010 from the Memorial Sloan-Kettering Cancer Center lymphoma database, the Stanford Cancer Center Registry, and the National Cancer Institute (NCI) pediatric lymphoma database...
February 2012: Clinical Lymphoma, Myeloma & Leukemia
Samata Basani, Abhimanyu Garg
CONTEXT: Bexarotene is a retinoid X receptor agonist, which is currently used for the treatment of cutaneous T-cell lymphoma (CTCL). It is known to induce central hypothyroidism as well as dyslipidemia including elevation of triglycerides (TG) and low-density lipoprotein cholesterol along with slight lowering of high-density lipoprotein cholesterol (HDL-C). Marked lowering of HDL-C has never been previously reported in bexarotene-treated patients and whether it is related to hypothyroidism remains unclear...
November 2015: Journal of Clinical Lipidology
Santosh K Misra, Goutam Ghoshal, Manas R Gartia, Zhe Wu, Arun K De, Mao Ye, Corinne R Bromfield, Emery M Williams, Kuldeep Singh, Krishnarao V Tangella, Laurie Rund, Klaus Schulten, Lawrence B Schook, Partha S Ray, Everette C Burdette, Dipanjan Pan
Repurposing of existing cancer drugs to overcome their physical limitations, such as insolubility, represents an attractive strategy to achieve enhanced therapeutic efficacy and broaden the range of clinical applications. Such an approach also promises to offer substantial cost savings in drug development efforts. Here we repurposed FDA-approved topical agent bexarotene (Targretin), currently in limited use for cutaneous manifestations of T-cell lymphomas, and re-engineer it for use in solid tumor applications by forming self-assembling nanobubbles...
November 24, 2015: ACS Nano
Eugene O'Hare, Ross Jeggo, Eun-Mee Kim, Bridgeen Barbour, Jean-Sebastien Walczak, Philip Palmer, Taylor Lyons, Deaglan Page, Donncha Hanna, Jolyon R Meara, David Spanswick, Jian-Ping Guo, Edith G McGeer, Patrick L McGeer, Peter Hobson
Bexarotene has been reported to reduce brain amyloid-β (Aβ) levels and to improve cognitive function in transgenic mouse models of Alzheimer's disease (AD). Four groups failed to fully replicate the primary results but the original authors claimed overall support for the general conclusions. Because of its potential clinical importance, the current work studied the effects of bexarotene using two animal species and highly relevant paradigms. Rats were tested for the ability of bexarotene to prevent changes induced by an Aβ challenge in the form intracerebroventricular (i...
January 2016: Neuropharmacology
Leigh A Nattkemper, Maria-Estela Martinez-Escala, Ari B Gelman, Elisha M Singer, Alain H Rook, Joan Guitart, Gil Yosipovitch
Approximately 88% of cutaneous T-cell lymphoma (CTCL) patients are affected by pruritus that responds poorly to current antipruritic therapies. Interleukin (IL)-31, a Th2 cytokine, has been found to be increased in the serum of CTCL patients and to correlate with itch severity. This study investigated the role of IL-31 and its receptors (IL-31 receptor-alpha [IL-31RA] and OSMRβ) in the skin of CTCL patients with mild versus moderate/severe pruritus. Expression levels of IL-31, IL-31RA, and OSMRβ in the skin were measured using immunohistochemistry and correlated to pruritus severity and disease stage...
March 22, 2016: Acta Dermato-venereologica
Rakhshandra Talpur, Andrew Thompson, Pamela Gangar, Madeleine Duvic
BACKGROUND: This study aimed to assess the long-term tolerability of pralatrexate alone or in combination with oral bexarotene for relapsed or refractory mycosis fungoides (MF). PATIENTS AND METHODS: Patients with MF in this report were participants in 1 of 2 multicenter trials. During the dose-ranging phase I/II study, participants were treated with pralatrexate alone for 3 of 4 weeks. During a second phase I/II dose-ranging combination trial, participants were treated with pralatrexate at 15 mg/m(2)/wk for 3 of 4 weeks combined with 150 to 300 mg/m(2) of daily oral bexarotene...
August 2014: Clinical Lymphoma, Myeloma & Leukemia
Serena Rupoli, Lucia Canafoglia, Gaia Goteri, Pietro Leoni, Giuliano Brandozzi, Irene Federici, Giorgia Micucci, Federica Giantomassi, Giorgio Mozzicafreddo, Renato Alterini, Giorgio Filosa, Giuseppe Ricotti, Marco Simonacci, Anna Rita Scortechini, Antonio Zizzi, Nicola Pimpinelli
INTRODUCTION: Bexarotene is a synthetic retinoid effective in early and advanced stages of mycosis fungoides (MF)/Sezary Syndrome (SS) both in monotherapy and combination schemes. We aimed to assess disease response to low-dose bexarotene and PUVA in maintenance in refractory and/or resistant patients with early and advanced stage MF/SS. METHODS: We followed prospectively 21 patients (stages IB-IV): 15 with early stage MF and 6 with advanced disease. "Mini" and standard protocols were respectively applied to patients who failed PUVA or several systemic regimens...
January 2016: European Journal of Dermatology: EJD
M Estela Martinez-Escala, Timothy M Kuzel, Jason B Kaplan, Adam Petrich, Beatrice Nardone, Steven T Rosen, Joan Guitart
IMPORTANCE: Romidepsin is a histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma (CTCL). Durable responses have been published without establishing a standard recommendation about duration of treatment. OBJECTIVE: To review the long-term use of romidepsin in responders who received a dose-sparing regimen. DESIGN, SETTING, AND PARTICIPANTS: Retrospective review of medical records of patients with a diagnosis of CTCL, including mycosis fungoides (MF), Sézary syndrome (SS), or CTCL not otherwise specified seen at a multidisciplinary clinic at Northwestern University from 2009 until December 2014...
June 1, 2016: JAMA Oncology
Sumana Devata, Ryan A Wilcox
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of extranodal lymphomas involving the skin. Diagnosis of the two main subtypes of CTCL-mycosis fungoides (MF) and Sézary syndrome (SS)-is based on the International Society for Cutaneous Lymphomas/European Organization for Research and Treatment of Cancer (ISCL/EORTC) classification system, which utilizes clinical, histopathological, molecular biologic, and immunopathologic features. Risk stratification, based on TNMB (tumor, node, metastasis, and blood) staging, provides prognostic information, with limited-stage disease conferring the longest median overall survival...
June 2016: American Journal of Clinical Dermatology
Rajan Dewar, Aleodor Alexandru Andea, Joan Guitart, Daniel A Arber, Lawrence M Weiss
CONTEXT: Primary cutaneous lymphoma is a common extranodal non-Hodgkin lymphoma. These lesions share common features with their nodal counterparts, but also have differences in morphology, unique clinical presentations, and immunohistochemical features. OBJECTIVE: To review the 2008 World Health Organization (WHO) and 2005 consensus WHO-EORTC (European Organisation for Research and Treatment of Cancer) classifications, and address the immunohistochemical findings in the most common primary cutaneous T- and B-cell lymphomas...
March 2015: Archives of Pathology & Laboratory Medicine
Michelle A Fanale, Steven M Horwitz, Andres Forero-Torres, Nancy L Bartlett, Ranjana H Advani, Barbara Pro, Robert W Chen, Andrew Davies, Tim Illidge, Dirk Huebner, Dana A Kennedy, Andrei R Shustov
PURPOSE: Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50%. This phase I open-label study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP or in combination with CHP (CHOP without vincristine) as front-line treatment in patients with CD30(+) PTCL. PATIENTS AND METHODS: Patients received sequential treatment (once every 3 weeks) with brentuximab vedotin 1...
October 1, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Xiao Ni, Jeffrey L Jorgensen, Meghali Goswami, Pramoda Challagundla, William K Decker, Youn H Kim, Madeleine A Duvic
PURPOSE: The CC chemokine receptor 4 (CCR4) is expressed on malignant T cells in cutaneous T-cell lymphoma (CTCL) as well as on regulatory T cells (Treg). When mogamulizumab, a defucosylated monoclonal antibody, binds to CCR4, it induces antibody-dependent cellular cytotoxicity against CCR4(+) malignant T cells. The goal of this study was to determine the effect of mogamulizumab on CCR4(+) Tregs in patients with CTCL. EXPERIMENTAL DESIGN: Peripheral blood of 24 patients with CTCL participating in a phase I/II trial was analyzed for CCR4 expression on different T-cell subsets by flow cytometry, before and after one course of mogamulizumab...
January 15, 2015: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
L E Selman, T Beynon, E Radcliffe, S Whittaker, D Orlowska, F Child, R Harding
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is a rare, progressive cancer that can be life limiting and highly disfiguring. Patients with CTCL experience poor quality of life; however, there is little published about the experiences of their families. OBJECTIVES: To describe the impact of CTCL on family members and how they cope and adjust, to inform support services. METHODS: Semistructured qualitative interviews were conducted with adult informal caregivers of patients with CTCL recruited via a supraregional CTCL clinic...
June 2015: British Journal of Dermatology
J Eder, A Kern, J Moser, M Kitzwögerer, R Sedivy, F Trautinger
BACKGROUND: Primary cutaneous lymphomas (PCL) are a heterogenous group of rare lymphoid neoplasms with incomplete information on global and regional prevalence. The recently introduced lymphoma classifications define distinctive clinicopathological disease entities that should allow for more accurate epidemiological assessment. OBJECTIVE: The aim of this study was to evaluate the prevalence and clinical spectrum of PCL diagnosed and treated at the Department of Dermatology and Venereology in St...
August 2015: Journal of the European Academy of Dermatology and Venereology: JEADV
Madeleine Duvic, Lauren C Pinter-Brown, Francine M Foss, Lubomir Sokol, Jeffrey L Jorgensen, Pramoda Challagundla, Karen M Dwyer, Xiaoping Zhang, Michael R Kurman, Rocco Ballerini, Li Liu, Youn H Kim
This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma. No dose-limiting toxicity was observed and the maximum tolerated dose was not reached in phase 1 after IV infusion of mogamulizumab (0.1, 0.3, and 1.0 mg/kg) once weekly for 4 weeks followed by a 2-week observation. In phase 2, patients were dosed with 1.0 mg/kg mogamulizumab according to the same schedule for the first course followed by infusion every 2 weeks during subsequent courses until disease progression...
March 19, 2015: Blood
Larisa J Geskin, Sara Viragova, Donna B Stolz, Patrizia Fuschiotti
Cutaneous T-cell lymphomas (CTCLs) primarily affect skin and are characterized by proliferation of mature CD4(+) T-helper cells. The pattern of cytokine production in the skin and blood is considered to be of major importance for the pathogenesis of CTCLs. Abnormal cytokine expression in CTCLs may be responsible for enhanced proliferation of the malignant cells and/or depression of the antitumor immune response. Here we show that interleukin-13 (IL-13) and its receptors IL-13Rα1 and IL-13Rα2 are highly expressed in the clinically involved skin of CTCL patients...
April 30, 2015: Blood
A Fauconneau, A Pham-Ledard, D Cappellen, E Frison, M Prochazkova-Carlotti, M Parrens, S Dalle, P Joly, R Viraben, F Franck, S Ingen-Housz-Oro, D Giacchero, M-L Jullié, B Vergier, J-P Merlio, M Beylot-Barry
BACKGROUND: Transformed mycosis fungoides (TMF) large cells may express CD30 antigen, and because of this, the differential diagnosis between CD30-rich TMF and primary cutaneous anaplastic large-cell lymphoma (cALCL) may be difficult, and especially in distinguishing cALCL associated with MF vs. CD30-rich TMF. OBJECTIVES: To find clinical, histological and molecular diagnostic features useful for differential diagnosis between cALCL and CD30-rich TMF. To analyse and compare the prognostic value of clinical and pathological factors in these two diseases...
June 2015: British Journal of Dermatology
Manisha R Panchal, Julia J Scarisbrick
Cutaneous T-cell lymphoma (CTCL) is an umbrella term that encompasses a group of neoplasms that have atypical T-lymphocytes in the skin. Mycosis fungoides (MF) is the most common type of CTCL and Sézary syndrome (SS) is the leukemic form. Treatment for CTCL is dependent on the stage of disease and response to previous therapy. Therapy is divided into skin-directed treatment, which tends to be first line for early-stage disease, and systemic therapy, which is reserved for refractory CTCL. Bexarotene is a rexinoid and was licensed in Europe in 2002 for use in patients with advanced disease that have been refractory to a previous systemic treatment...
2015: OncoTargets and Therapy
2015-02-15 23:15:07
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"